NCT02079896View on ClinicalTrials.gov

Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
AnemiaEnd Stage Renal Disease
Interventions
DRUG

Lexaptepid pegol (NOX-H94)

anti-hepcidin L-RNA-aptamer (Spiegelmer)

DRUG

Placebo

Trial Locations (10)

Unknown

Dialysis Unit, Düsseldorf

University Hospital, Halle

Hospital, Leipzig

Dialysis Unit, Villingen-Schwenningen

Hospital, Siena

Hospital, Swansea

Hospital, Leicester

Hospital, London

King's College London, London

Lister Hospital, Stevenage

All Listed Sponsors
lead

TME Pharma AG

INDUSTRY

NCT02079896 - Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients | Biotech Hunter | Biotech Hunter